Physician profile
Daniel Zandman
NPI 1780842955
$5,929.77
in general payments reported to CMS, 2019-2025
22 companies · $36.39 in 2025
The $36.39 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,571 · 2020: $446 · 2021: $1,530 · 2022: $2,043 · 2023: $207 · 2024: $96.55 · 2025: $36.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279 · Education: $60.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.73 |
| Education | $60.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,916.00 | 2022 | |
| Abbvie INC. | $701.61 | 2019-2021 | |
| Braintree Laboratories, INC. | $669.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $589.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $557.75 | 2019-2021 | |
| Pfizer INC. | $420.84 | 2019-2024 | |
| Janssen Biotech, INC. | $182.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $171.53 | 2019-2023 | Verquvo |
| Gilead Sciences, INC. | $131.92 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $116.33 | 2019-2023 | Cimzia |
| Celgene Corporation | $90.48 | 2021 | |
| Allergan, INC. | $70.95 | 2019 | |
| Ucb, INC. | $49.62 | 2019 | |
| Ironwood Pharmaceuticals, INC | $41.78 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $39.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $36.39 | 2025 | |
| Covidien LP | $34.71 | 2020 | |
| Alfasigma USA, INC. | $31.71 | 2020 | |
| Aimmune Therapeutics, INC. | $28.19 | 2023 | |
| Redhill Biopharma INC. | $21.09 | 2021 | |
| Shire North American Group INC | $17.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zandman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.